| Standard of care (N = 31) | Alirocumab (N = 30) |
---|---|---|
Adverse cardiac events | 0 | 0 |
Cardiac death | 0 | 0 |
Myocardial infarction | 1 | 0 |
Ischemia driven target lesion revascularization, | Â | Â |
Treatment-related adverse events | 1 | 2 |
Nasopharyngitis | 1 | 2 |
Injection-site reaction | 0 | 1 |
Back pain | 1 | 1 |
Transaminase elevation | Â | Â |